Profile data is unavailable for this security.
About the company
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.
- Revenue in CAD (TTM)0.00
- Net income in CAD-17.21m
- Incorporated2006
- Employees5.00
- LocationBriacell Therapeutics Corp3rd FloorBellevue Centre,, 235-15th StrWEST VANCOUVER V7T 2X1CanadaCAN
- Phone+1 (604) 921-1810
- Fax+1 (604) 921-1898
- Websitehttps://briacell.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avicanna Inc | 22.07m | -7.25m | 32.77m | 38.00 | -- | -- | -- | 1.48 | -0.0808 | -0.0808 | 0.2477 | -0.0055 | 1.12 | 3.07 | 12.26 | 580,708.40 | -36.83 | -67.17 | -282.36 | -167.73 | 47.29 | 46.36 | -32.86 | -368.82 | 0.3163 | -10.44 | 0.1834 | -- | 314.82 | 169.57 | 40.67 | -- | -32.29 | -- |
| Thiogenesis Therapeutics Corp | 0.00 | -5.06m | 33.74m | -- | -- | 5.96 | -- | -- | -0.1289 | -0.1289 | 0.00 | 0.1241 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Medipharm Labs Corp | 36.99m | -13.61m | 34.42m | 166.00 | -- | 0.6889 | -- | 0.9305 | -0.0382 | -0.0382 | 0.1017 | 0.1234 | 0.600 | 3.44 | 3.90 | 222,831.30 | -22.07 | -32.88 | -26.27 | -39.56 | 16.37 | -5.88 | -36.78 | -67.66 | 2.20 | -- | 0.0407 | -- | 49.49 | 26.52 | 56.37 | -- | -49.66 | -- |
| Simply Better Brands Corp | 109.02m | -33.11m | 35.10m | -- | -- | -- | -- | 0.322 | -0.4616 | -0.4616 | 1.54 | -0.0684 | 2.84 | 6.79 | 22.87 | -- | -86.36 | -63.90 | -460.44 | -215.48 | 58.69 | -- | -30.37 | -29.46 | 0.298 | -8.19 | 1.65 | -- | 22.08 | -- | -96.41 | -- | -- | -- |
| Medicus Pharma Ltd | 0.00 | -8.02m | 35.62m | -- | -- | 32.30 | -- | -- | -1.25 | -1.25 | 0.00 | 0.0681 | 0.00 | -- | -- | -- | -539.96 | -652.37 | -- | -- | -- | -- | -- | -- | -- | -7.90 | 0.00 | -- | -- | -- | -300.86 | -- | -- | -- |
| Eastwood Bio-Medical Canada Inc | 736.75k | -531.60k | 37.97m | -- | -- | -- | -- | 51.54 | -0.0077 | -0.0077 | 0.0107 | -0.013 | 1.63 | -- | 38.65 | -- | -117.75 | -52.23 | -- | -140.29 | 60.00 | 52.09 | -72.15 | -52.90 | -- | -227.16 | -- | -- | -33.22 | 3.13 | -264.69 | -- | -- | -- |
| Briacell Therapeutics Corp | 0.00 | -17.21m | 38.48m | 5.00 | -- | -- | -- | -- | -1.11 | -1.11 | 0.00 | -0.6896 | 0.00 | -- | -- | -- | -54.70 | -59.37 | -60.36 | -63.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.35 | -- | -- | -- |
| Charlotte's Web Holdings Inc | 79.55m | -41.66m | 38.61m | 164.00 | -- | 0.6046 | -- | 0.4853 | -0.2716 | -0.2716 | 0.5182 | 0.4052 | 0.3668 | 1.07 | 27.08 | 485,053.90 | -19.21 | -25.71 | -22.16 | -29.03 | 55.88 | 48.98 | -52.37 | -63.11 | 2.33 | -- | 0.478 | -- | -14.82 | -1.90 | 59.88 | -- | -7.88 | -- |
| Medexus Pharmaceuticals Inc | 157.99m | 8.03m | 39.71m | 98.00 | 4.45 | 0.9818 | 2.48 | 0.2514 | 0.3637 | 0.3637 | 7.27 | 1.65 | 0.7547 | 2.19 | 5.44 | 1,612,120.00 | 3.83 | -6.83 | 8.44 | -9.79 | 52.91 | 53.90 | 5.08 | -11.45 | 0.7013 | 0.9426 | 0.6388 | -- | 40.93 | 69.17 | 142.41 | -- | -8.59 | -- |
| Immunoprecise Antibodies Ltd | 23.68m | -14.26m | 40.54m | 102.00 | -- | 0.8137 | -- | 1.71 | -0.4147 | -0.4147 | 0.6874 | 1.39 | 0.2939 | 5.25 | 6.76 | 170,046.20 | -17.70 | -23.62 | -19.62 | -27.25 | 51.88 | 57.18 | -60.23 | -76.18 | 1.38 | -- | 0.2241 | -- | 6.72 | 30.59 | -58.96 | -- | 34.04 | -- |
| Decibel Cannabis Company Inc | 115.96m | -1.77m | 40.99m | -- | -- | 0.8854 | 30.59 | 0.3535 | -0.0045 | -0.0045 | 0.2739 | 0.1129 | 0.817 | 1.51 | 7.66 | -- | -1.25 | -3.55 | -2.04 | -5.19 | 36.10 | 38.83 | -1.53 | -7.13 | 0.3685 | 1.21 | 0.5122 | -- | 46.18 | -- | 60.33 | -- | -32.45 | -- |
| IntelGenx Technologies Corp. | 1.43m | -15.06m | 41.92m | 48.00 | -- | -- | -- | 29.21 | -0.0862 | -0.0862 | 0.0082 | -0.1201 | 0.1245 | 14.36 | 1.74 | -- | -130.62 | -75.15 | -- | -133.79 | -66.03 | -- | -1,049.48 | -819.85 | 0.1153 | -4.88 | 23.66 | -- | 9.37 | -10.65 | 7.14 | -- | -30.32 | -- |
Data as of May 22 2024. Currency figures normalised to Briacell Therapeutics Corp's reporting currency: Canadian Dollar CAD
12.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Lynwood Capital Management, Inc.as of 31 Dec 2022 | 1.46m | 9.14% |
| Redmond Asset Management LLCas of 31 Mar 2024 | 133.07k | 0.83% |
| BMO Asset Management Corp.as of 31 Mar 2024 | 131.58k | 0.82% |
| KJ Harrison & Partners, Inc.as of 31 Mar 2024 | 87.04k | 0.55% |
| Onyx Bridge Wealth Group LLCas of 31 Mar 2024 | 50.00k | 0.31% |
| Summit Trail Advisors LLCas of 31 Mar 2024 | 35.00k | 0.22% |
| Sabby Management LLCas of 31 Mar 2024 | 34.22k | 0.21% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 21.46k | 0.13% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 17.80k | 0.11% |
| HighTower Advisors LLCas of 31 Mar 2024 | 14.45k | 0.09% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
